Search
tildrakizumab (Ilumya)
Indications:
- chronic plaque psoriasis*
* 80% with 75% clearance after etanercept failure [1]
* FDA-approved March 2018 [4]
Dosage:
- 100-200 mg every 4 weeks?
Mechanism of action:
- monoclonal antibody against IL-23 p19
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
dermatologic agent
References
- Bankhead C
American Academy of Dermatology Meeting Coverage 2017
Psoriasis Responds After Biologic Failure
- PASI-75 rate exceeds 80% with tildrakizumab.
http://www.medpagetoday.com/MeetingCoverage/AAD/63635
- American Academy of Dermatology
Reich K, et al
Tildrakizumab, ak selective anti-IL-23 monoclonal antibody, is
effective in subjects with chronic plaque psoriasis who do not
adequately respond to etanercept
American Academy of Dermatology (AAD) 2017; Abstract 5252.
- Papp K, et al
Maintenace of treatment response in chronic plaque psoriasis
patients continuing treatment or discontinuing treatment with
tildrakizumab in a 64-week, randomized controlled phase III
trial.
American Academy of Dermatology (AAD) 2017; Abstract 4885.
- Brooks M
FDA Clears Tildrakizumab (Ilumya ) for Plaque Psoriasis.
Medscape - Mar 21, 2018.
https://www.medscape.com/viewarticle/894314
- Thaci D, Piaserico S, Warren RB et al
Five-year efficacy and safety of tildrakizumab in patients with
moderate-to-severe psoriasis who respond at week 28: pooled analyses
of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).
Br J Dermatol. 2021 Aug;185(2):323-334
PMID: 33544883 Clinical Trial.
- Lebwohl MG, Leonardi CL, Mehta NN et al
Tildrakizumab efficacy, drug survival, and safety are comparable in patients
with psoriasis with and without metabolic syndrome: Long-term results from
2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).
J Am Acad Dermatol. 2021 Feb;84(2):398-407.
PMID: 32961255 Free article